Alpha-antitrypsin - Arriva/Hyland Immuno/Protease Sciences

Drug Profile

Alpha-antitrypsin - Arriva/Hyland Immuno/Protease Sciences

Alternative Names: Alpha-1 antitrypsin - Arriva/Hyland Immuno/Protease Sciences; Alpha-1 proteinase inhibitor - Arriva/Hyland Immuno/Protease Sciences; Inhaled rAAT - Arriva/Hyland Immuno/Protease Sciences; rAAT - Arriva/Hyland Immuno/Protease Sciences

Latest Information Update: 08 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protease Sciences
  • Developer Arriva Pharmaceuticals; Hyland Immuno
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action HIV protease inhibitors; Leucocyte elastase inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency; Cystic fibrosis

Highest Development Phases

  • Discontinued Alpha 1-antitrypsin deficiency; Chronic obstructive pulmonary disease; Cystic fibrosis; HIV infections; Otitis media; Viral hepatitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Feb 2008 Phase II development for alpha 1-antitrypsin deficiency is ongoing
  • 31 Oct 2006 Discontinued - Preclinical for Cystic fibrosis in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top